ASCO: Arvinas unveils first-in-human data for novel protein degrader in prostate cancer

Many widely used oncology therapies work by inhibiting cancer-related proteins. But what if we simply destroyed those proteins rather than trying to block their functions? That’s the idea behind the technology developed by Arvinas, which just offered a glimpse at first-in-human data for its lead product candidate.